R. Brouard - Concepedia

Author

R. Brouard

Sanofi (France)

Also Known As

R Brouard, R. Brouard, R??mi Brouard, RJ Brouard, Remi Brouard, Remi J Brouard, Rémi Brouard, Rémi Brouard

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

Sanofi (France)Lund University Pitié-Salpêtrière Hospital Sorbonne Université University of California, San Francisco

About

R. Brouard is an author at Sanofi (France) specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	507
2	Public Health	1	1	44
3	Allergy	1	1	104
4	Anatomy	1	1	10
5	Cellular Physiology	1	1	241

R. Brouard

Publications

Citations

H-Index

Page 1

	Year	Citations
Pharmacologic Chaperones as a Potential Treatment for X-Linked Nephrogenic Diabetes Insipidus Virginie Bernier, Jean-Pierre Morello, Alexandro Zarruk, Journal of the American Society of Nephrology PharmacotherapyCellular PhysiologyMutant V2 ReceptorsCreatinine ExcretionsChronic Kidney Disease	2005	241
Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women Mats Åkerlund, Thomas Bossmar, R. Brouard, BJOG An International Journal of Obstetrics & Gynaecology	1999	120
The effect of the NK2 tachykinin receptor antagonist SR 48968 (saredutant) on neurokinin A-induced bronchoconstriction in asthmatics Jan Van Schoor, G.F. Joos, BL Chasson, European Respiratory Journal AsthmaInflammatory Lung DiseaseLung InflammationImmunologyNk2 Receptor	1998	104
Short-term and Sustained Renal Effects of Angiotensin II Receptor Blockade in Healthy Subjects Michel Burnier, Michael Hagman, Jürg Nussberger, Hypertension	1995	95
The ATTEMPT cohort: a multi‐national longitudinal study of predictors, patterns and consequences of smoking cessation; introduction and evaluation of internet recruitment and data collection methods Robert West, Alicia Gilsenan, F Coste, Addiction	2006	65
Effect of SR49059, an orally active V<sub>1a</sub> vasopressin receptor antagonist, in the prevention of dysmenorrhoea R. Brouard, Thomas Bossmar, D. Fournié‐Lloret, BJOG An International Journal of Obstetrics & Gynaecology	2000	59
Effects of the Nonpeptide V <sub>1</sub> Vasopressin Receptor Antagonist SR49059 in Hypertensive Patients Marc Thibonnier, Ahmad Kilani, Mahboob Rahman, Hypertension	1999	45
The effect of relcovaptan (SR 49059), an orally active vasopressin V<sub>1a</sub>receptor antagonist, on uterine contractions in preterm labor Margareta Steinwall, Thomas Bossmar, R. Brouard, Gynecological Endocrinology Hormonal ContraceptiveUterine ContractionsPreterm LaborSr 49059Uterine Receptivity	2005	44
Clopidogrel Activities in Patients with Renal Function Impairment Gilbert Deray, Corinne Isnard Bagnis, R. Brouard, Clinical Drug Investigation Clopidogrel ActivitiesUrologyRenal FunctionMedicineChronic Kidney Disease	1998	44
Dose-Ranging Study of the Angiotensin II Receptor Antagonist Irbesartan (SR 47436/BMS-186295) on Blood Pressure and Neurohormonal Effects in Salt-Deplete Men Martin McIntyre, R J MacFadyen, P. A. Meredith, Journal of Cardiovascular Pharmacology Molecular PharmacologyHypertensionRenal FunctionCardiovascular DiseaseSalt-deplete Men	1996	27

Page 1